Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB040093 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| INCB040093 | EXPERIMENTAL | - |
| INCB040093 in combination with itacitinib (INCB039110) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INCB040093 | DRUG | Escalating doses starting at 100 mg every day (QD) |
| INCB040093 + itacitinib | DRUG | INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD. |
Inclusion Criteria: • Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows: \*Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma: EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma INCLUDING: any non-Hodgkin's B-cell malignancy such as C...
INCB040093 is an investigational small molecule being studied for the treatment of B-cell malignancies, a type of cancer that affects white blood cells called B lymphocytes. It is intended for patients with previously treated B-cell malignancies, meaning those whose disease has not responded to or has relapsed after prior therapy.
INCB040093 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. Incyte is conducting clinical research to evaluate the safety and efficacy of this investigational drug in patients with B-cell malignancies.
INCB040093 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested in clinical trials to assess its safety, tolerability, and potential efficacy in patients with B-cell malignancies.
INCB040093 has been studied in one completed Phase 1 clinical trial with the identifier NCT01905813. This trial, titled 'Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,' enrolled 121 participants in the United States. The study was not randomized or double-blind and included a control group.
INCB040093 is a small molecule, but its specific molecular target has not been disclosed in available information. As an investigational oncology drug, it is being studied for its potential to interfere with pathways involved in the growth and survival of malignant B cells, though the exact mechanism of action is not publicly detailed.